Symbols / BVS $8.99 +1.35%
BVS Chart
About
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 605.64M |
| Enterprise Value | 910.09M | Income | 22.73M | Sales | 568.09M |
| Book/sh | 2.74 | Cash/sh | 0.76 | Dividend Yield | — |
| Payout | 0.00% | Employees | 930 | IPO | — |
| P/E | 27.24 | Forward P/E | 10.29 | PEG | — |
| P/S | 1.07 | P/B | 3.28 | P/C | — |
| EV/EBITDA | 11.72 | EV/Sales | 1.60 | Quick Ratio | 1.12 |
| Current Ratio | 1.70 | Debt/Eq | 136.29 | LT Debt/Eq | — |
| EPS (ttm) | 0.33 | EPS next Y | 0.87 | EPS Growth | — |
| Revenue Growth | 2.80% | Earnings | 2026-05-05 | ROA | 4.99% |
| ROE | 13.17% | ROIC | — | Gross Margin | 68.33% |
| Oper. Margin | 13.76% | Profit Margin | 4.00% | Shs Outstand | 67.37M |
| Shs Float | 33.40M | Short Float | 5.53% | Short Ratio | 5.37 |
| Short Interest | — | 52W High | 10.13 | 52W Low | 5.81 |
| Beta | 0.72 | Avg Volume | 296.69K | Volume | 368.23K |
| Target Price | $15.00 | Recom | Strong_buy | Prev Close | $8.87 |
| Price | $8.99 | Change | 1.35% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.00
Mean price target
2. Current target
$8.99
Latest analyst target
3. DCF / Fair value
$7.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.99
Low
$14.00
High
$16.00
Mean
$15.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-06 | main | Barrington Research | Outperform → Outperform | $14 |
| 2026-03-06 | main | Craig-Hallum | Buy → Buy | $16 |
| 2026-02-09 | init | Barrington Research | — → Outperform | $13 |
| 2025-07-07 | init | Cantor Fitzgerald | — → Overweight | $12 |
| 2025-03-17 | main | Canaccord Genuity | Buy → Buy | $15 |
| 2024-12-17 | up | JP Morgan | Underweight → Neutral | $13 |
| 2024-11-06 | main | Canaccord Genuity | Buy → Buy | $15 |
| 2024-09-27 | main | Craig-Hallum | Buy → Buy | $17 |
| 2024-08-13 | main | Canaccord Genuity | Buy → Buy | $12 |
| 2024-08-07 | main | Craig-Hallum | Buy → Buy | $12 |
| 2024-05-08 | main | Canaccord Genuity | Buy → Buy | $8 |
| 2024-03-13 | main | Craig-Hallum | Buy → Buy | $9 |
| 2023-12-07 | up | Canaccord Genuity | Hold → Buy | $7 |
| 2023-04-03 | main | Craig-Hallum | — → Hold | $5 |
| 2022-11-30 | main | Goldman Sachs | — → Neutral | $3 |
| 2022-11-22 | down | Craig-Hallum | Buy → Hold | — |
| 2022-11-10 | main | Morgan Stanley | — → Overweight | $5 |
| 2022-11-09 | down | Canaccord Genuity | Buy → Hold | — |
| 2022-11-09 | down | JP Morgan | Overweight → Underweight | — |
| 2022-10-11 | main | Morgan Stanley | — → Overweight | $11 |
News
RSS: Latest BVS news- Bioventus (BVS) SVP granted RSUs, options and exercises prior awards - Stock Titan ue, 17 Mar 2026 21
- Bioventus (BVS) CFO receives major stock awards and exercises RSUs - Stock Titan ue, 17 Mar 2026 21
- Bioventus (NASDAQ:BVS) Director Michelle Mcmurry-Heath Sells 12,000 Shares - MarketBeat Sat, 14 Mar 2026 01
- BIOVENTUS ($BVS) Releases Q4 2025 Earnings - Quiver Quantitative hu, 05 Mar 2026 12
- Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily hu, 12 Mar 2026 09
- Those who invested in Bioventus (NASDAQ:BVS) three years ago are up 413% - Yahoo Finance ue, 10 Feb 2026 08
- Bioventus stock delivers 63% return after Fair Value signal - Investing.com hu, 12 Mar 2026 11
- Insider Sell: Michelle Mcmurry-heath Sells 12,000 Shares of Biov - GuruFocus Sat, 14 Mar 2026 02
- Bioventus (BVS) SVP & General Counsel receives RSU, option grants and exercises awards - Stock Titan ue, 17 Mar 2026 21
- Divisadero Street Capital Management LP Sells 385,116 Shares of Bioventus Inc. $BVS - MarketBeat Mon, 16 Mar 2026 09
- Institutional investors own a significant stake of 36% in Bioventus Inc. (NASDAQ:BVS) - Yahoo Finance Wed, 14 Jan 2026 08
- Bioventus (BVS) CEO adds major RSU and option grants, exercises awards - Stock Titan ue, 17 Mar 2026 21
- Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat Fri, 13 Mar 2026 04
- Bioventus (NYSE:BVS) Stock Price Down 0.1% - Should You Sell? - MarketBeat ue, 03 Mar 2026 08
- Bioventus (BVS) director logs open-market sale of 12,000 shares - Stock Titan Fri, 13 Mar 2026 21
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 12000 | 105439.0 | — | Sale at price 8.79 per share. | MCMURRY-HEATH MICHELLE | Director | — | 2026-03-11 00:00:00 | D |
| 1 | 4375 | nan | — | — | CHURCH KATRINA J | Officer | — | 2026-02-13 00:00:00 | D |
| 2 | 12980 | nan | — | — | D'ADAMIO ANTHONY | General Counsel | — | 2026-02-13 00:00:00 | D |
| 3 | 20153 | nan | — | — | SINGLETON MARK LEONARD | Chief Financial Officer | — | 2026-02-13 00:00:00 | D |
| 4 | 93750 | nan | — | — | CLAYPOOLE ROBERT E. | Chief Executive Officer | — | 2026-01-09 00:00:00 | D |
| 5 | 10000 | 75658.0 | — | Sale at price 7.57 per share. | NOHRA GUY P | Director | — | 2025-12-04 00:00:00 | D |
| 6 | 17701 | 131255.0 | — | Sale at price 7.42 per share. | MCMURRY-HEATH MICHELLE | Director | — | 2025-11-07 00:00:00 | D |
| 7 | 7575 | nan | — | — | BARTHOLDSON JOHN A | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-06 00:00:00 | D |
| 8 | 26493 | nan | — | — | NOHRA GUY P | Director | — | 2025-06-02 00:00:00 | D |
| 9 | 26493 | nan | — | — | SUTTER MARTIN P | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-02 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -554.82K | -3.84M | -17.59M | -31.16M |
| TaxRateForCalcs | 0.21 | 0.10 | 0.21 | 0.23 |
| NormalizedEBITDA | 101.85M | 74.03M | 60.68M | 10.97M |
| TotalUnusualItems | -2.64M | -38.02M | -83.75M | -132.58M |
| TotalUnusualItemsExcludingGoodwill | -2.64M | -38.02M | -83.75M | -132.58M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 22.73M | -36.12M | -81.80M | -89.96M |
| ReconciledDepreciation | 47.01M | 49.55M | 57.37M | 55.40M |
| ReconciledCostOfRevenue | 138.65M | 143.15M | 135.63M | 135.39M |
| EBITDA | 99.21M | 36.01M | -23.07M | -121.61M |
| EBIT | 52.20M | -13.55M | -80.44M | -177.00M |
| NetInterestIncome | -26.49M | -38.79M | -40.68M | -12.02M |
| InterestExpense | 26.49M | 38.79M | 40.68M | 12.02M |
| NormalizedIncome | 24.82M | -1.95M | -15.64M | 11.46M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 22.73M | -36.12M | -156.23M | -158.70M |
| TotalExpenses | 511.80M | 550.46M | 510.32M | 546.77M |
| TotalOperatingIncomeAsReported | 53.98M | -15.20M | -81.72M | -167.23M |
| DilutedAverageShares | 64.55M | 62.65M | 61.39M | 45.47M |
| BasicAverageShares | 64.55M | 62.65M | 61.39M | 45.47M |
| DilutedEPS | -0.56 | -2.49 | -2.59 | -0.15 |
| BasicEPS | -0.56 | -2.49 | -2.59 | -0.15 |
| DilutedNIAvailtoComStockholders | 22.73M | -36.12M | -156.23M | -158.70M |
| NetIncomeCommonStockholders | 22.73M | -36.12M | -156.23M | -158.70M |
| NetIncome | 22.73M | -36.12M | -156.23M | -158.70M |
| MinorityInterests | -4.54M | 10.92M | 39.40M | 54.69M |
| NetIncomeIncludingNoncontrollingInterests | 27.27M | -47.05M | -195.62M | -213.39M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | -74.43M | -68.74M |
| NetIncomeContinuousOperations | 27.27M | -47.05M | -121.20M | -144.65M |
| TaxProvision | -1.56M | -5.29M | 85.00K | -44.37M |
| PretaxIncome | 25.71M | -52.34M | -121.11M | -189.03M |
| OtherIncomeExpense | -4.10M | -36.38M | -82.46M | -142.35M |
| OtherNonOperatingIncomeExpenses | -1.45M | 1.65M | 1.29M | -9.77M |
| SpecialIncomeCharges | -2.64M | -38.02M | -83.75M | -132.58M |
| GainOnSaleOfPPE | -81.00K | -292.00K | -3.58M | 0.00 |
| OtherSpecialCharges | 326.00K | |||
| WriteOff | 0.00 | 0.00 | 5.67M | |
| ImpairmentOfCapitalAssets | 0.00 | 36.36M | 78.61M | 124.70M |
| RestructuringAndMergernAcquisition | 2.23M | 1.37M | 1.56M | 7.88M |
| NetNonOperatingInterestIncomeExpense | -26.49M | -38.79M | -40.68M | -12.02M |
| InterestExpenseNonOperating | 26.49M | 38.79M | 40.68M | 12.02M |
| OperatingIncome | 56.29M | 22.82M | 2.03M | -34.66M |
| OperatingExpense | 331.87M | 365.40M | 326.17M | 365.74M |
| DepreciationAmortizationDepletionIncomeStatement | 5.73M | 7.65M | 8.84M | 9.75M |
| DepreciationAndAmortizationInIncomeStatement | 5.73M | 7.65M | 8.84M | 9.75M |
| ResearchAndDevelopment | 12.11M | 13.95M | 13.45M | 23.85M |
| SellingGeneralAndAdministration | 314.03M | 343.80M | 303.88M | 332.13M |
| GrossProfit | 388.16M | 388.23M | 328.19M | 331.08M |
| CostOfRevenue | 179.93M | 185.05M | 184.15M | 181.04M |
| TotalRevenue | 568.09M | 573.28M | 512.35M | 512.12M |
| OperatingRevenue | 568.09M | 573.28M | 512.35M | 512.12M |
| Line Item | 2023-12-31 | 2022-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 0.00 | ||
| OrdinarySharesNumber | 67.10M | 65.76M | 63.27M | 62.06M |
| ShareIssued | 67.10M | 65.76M | 63.27M | 62.06M |
| NetDebt | 242.71M | 294.05M | 357.88M | 387.88M |
| TotalDebt | 293.95M | 335.63M | 394.85M | 418.07M |
| TangibleBookValue | -191.78M | -264.25M | -316.22M | -322.07M |
| InvestedCapital | 478.06M | 483.57M | 568.44M | 743.30M |
| WorkingCapital | 112.46M | 65.21M | 92.50M | -31.44M |
| NetTangibleAssets | -191.78M | -264.25M | -316.22M | -322.07M |
| CommonStockEquity | 184.10M | 147.94M | 173.59M | 325.24M |
| TotalCapitalization | 463.06M | 456.23M | 540.59M | 710.25M |
| TotalEquityGrossMinorityInterest | 228.45M | 185.60M | 221.12M | 412.22M |
| MinorityInterest | 44.34M | 37.66M | 47.53M | 86.98M |
| StockholdersEquity | 184.10M | 147.94M | 173.59M | 325.24M |
| GainsLossesNotAffectingRetainedEarnings | -1.90M | -2.57M | 794.00K | -110.00K |
| OtherEquityAdjustments | -1.90M | -2.57M | 794.00K | -110.00K |
| RetainedEarnings | -334.93M | -357.66M | -321.54M | -165.31M |
| AdditionalPaidInCapital | 520.85M | 508.09M | 494.25M | 490.58M |
| CapitalStock | 83.00K | 82.00K | 79.00K | 78.00K |
| CommonStock | 83.00K | 82.00K | 79.00K | 78.00K |
| TotalLiabilitiesNetMinorityInterest | 455.11M | 542.35M | 589.79M | 960.43M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 294.73M | 331.95M | 414.30M | 656.41M |
| OtherNonCurrentLiabilities | 15.35M | 23.10M | 46.08M | 40.24M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 228.91M | ||
| NonCurrentDeferredLiabilities | 433.00K | 564.00K | 1.21M | 2.25M |
| NonCurrentDeferredTaxesLiabilities | 433.00K | 564.00K | 1.21M | 2.25M |
| LongTermDebtAndCapitalLeaseObligation | 278.95M | 308.29M | 367.00M | 385.01M |
| LongTermDebt | 278.95M | 308.29M | 367.00M | 385.01M |
| CurrentLiabilities | 160.38M | 210.40M | 175.50M | 304.02M |
| OtherCurrentLiabilities | 21.06M | 43.53M | 24.52M | 139.64M |
| CurrentDeferredLiabilities | 117.61M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 15.00M | 27.34M | 27.85M | 33.06M |
| CurrentDebt | 15.00M | 27.34M | 27.85M | 33.06M |
| OtherCurrentBorrowings | 15.00M | 27.34M | 27.85M | 33.06M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.56M | 7.60M | 9.71M | 11.43M |
| PayablesAndAccruedExpenses | 117.76M | 131.93M | 113.42M | 119.89M |
| CurrentAccruedExpenses | 101.69M | 104.38M | 85.64M | 80.62M |
| InterestPayable | 3.17M | 5.32M | 6.61M | 217.00K |
| Payables | 16.06M | 27.56M | 27.79M | 39.27M |
| TotalTaxPayable | 5.13M | 3.87M | 4.75M | 2.57M |
| AccountsPayable | 10.93M | 23.69M | 23.04M | 36.70M |
| TotalAssets | 683.56M | 727.96M | 810.91M | 1.37B |
| TotalNonCurrentAssets | 410.72M | 452.35M | 542.91M | 1.10B |
| OtherNonCurrentAssets | 2.29M | 1.89M | 3.14M | 408.62M |
| NonCurrentDeferredAssets | 5.52M | 4.75M | 0.00 | 0.00 |
| NonCurrentDeferredTaxesAssets | 5.52M | 4.75M | 0.00 | 0.00 |
| InvestmentsAndAdvances | 2.64M | 29.29M | ||
| GoodwillAndOtherIntangibleAssets | 375.88M | 412.19M | 489.81M | 647.31M |
| OtherIntangibleAssets | 368.42M | 404.73M | 482.35M | 639.85M |
| Goodwill | 7.46M | 7.46M | 7.46M | 7.46M |
| NetPPE | 27.02M | 33.52M | 49.96M | 44.15M |
| AccumulatedDepreciation | -54.26M | -50.19M | -40.50M | -30.79M |
| GrossPPE | 81.28M | 83.70M | 90.46M | 74.94M |
| Leases | 4.34M | 4.09M | 3.76M | 3.35M |
| OtherProperties | 32.21M | 32.21M | 42.50M | 33.52M |
| MachineryFurnitureEquipment | 44.73M | 47.40M | 44.20M | 38.07M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 272.84M | 275.61M | 268.00M | 272.57M |
| OtherCurrentAssets | 11.06M | 14.16M | 16.91M | 18.55M |
| AssetsHeldForSaleCurrent | 0.00 | 2.78M | ||
| RestrictedCash | 23.00K | 5.28M | ||
| PrepaidAssets | 4.44M | 12.24M | ||
| Inventory | 82.24M | 92.47M | 91.33M | 84.77M |
| InventoriesAdjustmentsAllowances | -1.85M | -1.33M | ||
| FinishedGoods | 61.00M | 70.38M | 70.27M | 66.31M |
| RawMaterials | 21.24M | 22.10M | 21.06M | 18.45M |
| Receivables | 128.30M | 127.39M | 122.79M | 136.29M |
| AccountsReceivable | 128.30M | 127.39M | 122.79M | 136.29M |
| AllowanceForDoubtfulAccountsReceivable | -2.90M | -2.86M | -4.22M | -7.02M |
| GrossAccountsReceivable | 131.21M | 130.26M | 127.01M | 143.32M |
| CashCashEquivalentsAndShortTermInvestments | 51.24M | 41.58M | 36.96M | 30.19M |
| CashAndCashEquivalents | 51.24M | 41.58M | 36.96M | 30.19M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 72.11M | 37.79M | 7.98M | -15.02M |
| RepaymentOfDebt | -119.82M | -59.58M | -87.26M | -45.04M |
| IssuanceOfDebt | 76.91M | 0.00 | 64.00M | 104.66M |
| IssuanceOfCapitalStock | 2.07M | 2.44M | 778.00K | 5.82M |
| CapitalExpenditure | -2.56M | -1.01M | -7.36M | -1.48M |
| EndCashPosition | 51.24M | 41.58M | 36.96M | 31.84M |
| BeginningCashPosition | 41.58M | 36.96M | 31.84M | 99.21M |
| EffectOfExchangeRateChanges | 371.00K | -2.56M | 629.00K | 521.00K |
| ChangesInCash | 9.29M | 7.18M | 4.50M | -67.90M |
| FinancingCashFlow | -62.14M | -54.58M | -26.65M | 62.08M |
| CashFlowFromContinuingFinancingActivities | -62.14M | -54.58M | -26.65M | 62.08M |
| NetOtherFinancingCharges | -21.30M | 2.56M | -4.17M | -3.37M |
| CashDividendsPaid | 0.00 | -367.00K | ||
| CommonStockDividendPaid | 0.00 | -367.00K | ||
| NetCommonStockIssuance | 2.07M | 2.44M | 778.00K | 5.82M |
| CommonStockIssuance | 2.07M | 2.44M | 778.00K | 5.82M |
| NetIssuancePaymentsOfDebt | -42.91M | -59.58M | -23.26M | 59.62M |
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | -20.00M | |||
| ShortTermDebtIssuance | 20.00M | |||
| NetLongTermDebtIssuance | -42.91M | -59.58M | -23.26M | 59.62M |
| LongTermDebtPayments | -119.82M | -59.58M | -87.26M | -45.04M |
| LongTermDebtIssuance | 76.91M | 0.00 | 64.00M | 104.66M |
| InvestingCashFlow | -3.25M | 22.96M | 15.81M | -116.44M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 0.00 | -11.51M | -104.84M |
| CashFlowFromContinuingInvestingActivities | -3.25M | 22.96M | 27.31M | -11.60M |
| NetOtherInvestingChanges | -75.00K | |||
| NetInvestmentPurchaseAndSale | 0.00 | -709.00K | 0.00 | -10.04M |
| NetBusinessPurchaseAndSale | -686.00K | 24.68M | 34.67M | 0.00 |
| SaleOfBusiness | 24.68M | 34.67M | 0.00 | 0.00 |
| PurchaseOfBusiness | -686.00K | 0.00 | -104.84M | -262.87M |
| NetIntangiblesPurchaseAndSale | 0.00 | -1.48M | -7.37M | |
| PurchaseOfIntangibles | 0.00 | -1.48M | -7.37M | |
| NetPPEPurchaseAndSale | -2.56M | -1.01M | -7.36M | -1.48M |
| PurchaseOfPPE | -2.56M | -1.01M | -7.36M | -1.48M |
| OperatingCashFlow | 74.67M | 38.80M | 15.34M | -13.54M |
| CashFromDiscontinuedOperatingActivities | 0.00 | 0.00 | -2.17M | -2.13M |
| CashFlowFromContinuingOperatingActivities | 74.67M | 38.80M | 17.51M | -11.41M |
| ChangeInWorkingCapital | -13.84M | -11.78M | -3.18M | -29.73M |
| ChangeInOtherWorkingCapital | -1.68M | -2.52M | -1.97M | 9.66M |
| ChangeInPayablesAndAccruedExpense | -19.81M | 17.85M | -5.28M | -3.10M |
| ChangeInInventory | 8.57M | -16.43M | -5.99M | -18.62M |
| ChangeInReceivables | -916.00K | -10.67M | 10.05M | -17.67M |
| ChangesInAccountReceivables | -916.00K | -10.67M | 10.05M | -17.67M |
| OtherNonCashItems | 1.16M | 4.23M | 2.43M | 1.49M |
| StockBasedCompensation | 12.67M | 13.27M | 2.72M | 17.59M |
| ProvisionandWriteOffofAssets | 1.26M | -434.00K | -1.10M | 5.19M |
| AssetImpairmentCharge | 0.00 | 36.36M | 78.61M | 134.98M |
| DeferredTax | -909.00K | -5.39M | -2.38M | -46.66M |
| DeferredIncomeTax | -909.00K | -5.39M | -2.38M | -46.66M |
| DepreciationAmortizationDepletion | 47.01M | 49.55M | 57.37M | 55.40M |
| DepreciationAndAmortization | 47.01M | 49.55M | 57.37M | 55.40M |
| OperatingGainsLosses | 47.00K | 33.00K | 4.24M | -5.01M |
| PensionAndEmployeeBenefitExpense | 0.00 | 0.00 | -24.36M | |
| GainLossOnInvestmentSecurities | -6.40M | -2.73M | ||
| NetForeignCurrencyExchangeGainLoss | -360.00K | -259.00K | 665.00K | 1.38M |
| NetIncomeFromContinuingOperations | 27.27M | -47.05M | -121.20M | -144.65M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BVS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|